SciSparc
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 3
- Market Cap
- -
- Website
- http://www.scisparc.com
- Introduction
SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.
SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)
- Conditions
- Autism Spectrum Disorder (ASD)
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- SciSparc
- Target Recruit Count
- 60
- Registration Number
- NCT05182697
- Locations
- 🇮🇱
Clinical Research Center and Negev Autism Center Soroka University Medical Center, Be'er-Sheva, Israel, Be'er-Sheva, Israel
SCI-110 in the Treatment of Tourette Syndrome
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- SciSparc
- Target Recruit Count
- 164
- Registration Number
- NCT05126888
- Locations
- 🇺🇸
Yale Child Study Center - NIHB 205, New Haven, Connecticut, United States
🇩🇪Medizinische Hochschule Hannover, Hannover, Germany
🇮🇱Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome
- Conditions
- Tourette Syndrome
- Interventions
- Drug: PlaceboDrug: THX-110 (dronabinol plus PEA)
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- SciSparc
- Target Recruit Count
- 60
- Registration Number
- NCT03651726
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Hannover, Germany
🇩🇪LMU Klinikum der Universität München, Klinik für Psychiatrie und Psychotherapie, Munich, Germany
A Study to Examine the Efficacy of a Therapeutic THX-110 for Obstructive Sleep Apnea
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- SciSparc
- Target Recruit Count
- 30
- Registration Number
- NCT03646552
- Locations
- 🇮🇱
Assuta HaShalom, Tel Aviv, Israel